Developer docs
API playgroundTry for free, no card

Search company profiles

Goodwin Biotechnology

Full company profile

uuid0003313

Namestring
Goodwin Biotechnology
Legal namestring
Goodwin Biotechnology Inc.
Websiteurl
goodwinbio.com
Company typeenum
Private
Founded yearint
1991
Descriptiontext

Goodwin Biotechnology, now operating as GBI Biomanufacturing, is a full-service biopharmaceutical contract development and manufacturing organization (CDMO) founded in 1991 and headquartered in Plantation, Florida. The company delivers an integrated platform branded as the Single-Source Solution™, which spans the full biologics manufacturing value chain: upstream cell culture development, cGMP cell banking, downstream purification, cGMP clinical and commercial manufacturing, bioconjugation, aseptic fill and finish, stability testing, and analytical method development and characterization. These core manufacturing services are wrapped with regulatory/CMC support, project management, manufacturing strategy consulting, and quality systems built on a Quality by Design framework.

The company serves biopharmaceutical companies — particularly those developing complex biologic therapeutics, biosimilars, and targeted-delivery biologics requiring bioconjugation — by reducing manufacturing risk and providing integrated development-through-commercial capabilities under one roof. Its go-to-market is direct B2B enterprise sales, supported by participation in industry events (BIO International Convention, BioFlorida) and content marketing. Revenue mechanics are fee-for-service project-based contracts, with pricing determined per engagement; no public rate cards exist. The company is privately held with 51–100 employees, has raised at least $20.7M in disclosed funding (April 2019), and is currently expanding its Broward County facility (May 2026) to add stem cell production capacity targeting Florida's regenerative medicine market.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersFort Lauderdale, United States
HQ citystring
Fort Lauderdale
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical CDMO services, biologics contract manufacturing, cGMP manufacturing services, bioconjugation services, aseptic fill finish
Industry3 codes
1Biologics (mAbs/Recombinant Proteins) CDMO
CodeHLAGABACPrimaryYes
2Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
CodeHLAGAGAAPrimaryNo
3Clinical Trial Material (CTM) Manufacturing & Supply CDMO
CodeHLAGABAKPrimaryNo
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Contract Manufacturing
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Manufacturing Services
TypeProfessional Services
Description

Fee-for-service contract manufacturing model providing preclinical, clinical, and commercial manufacturing services for biopharmaceutical companies. Revenue generated through project-based engagements across development and manufacturing phases.

gbibio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Goodwin Biotechnology, operating as GBI Biomanufacturing, is a full-service biopharmaceutical contract development and manufacturing organization (CDMO) that delivers integrated biologics manufacturing services from upstream cell culture development through cGMP clinical and commercial manufacturing, bioconjugation, aseptic fill and finish, stability testing, and analytical characterization. Its Single-Source Solution platform combines development, manufacturing, and project support under one roof for biotech and pharma clients producing complex biologic therapeutics, biosimilars, and regenerative medicine products.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

GBI (formerly Goodwin Biotechnology) is a full-service biopharmaceutical CDMO (Contract Development and Manufacturing Organization) based in Florida that offers a unified platform called Single-Source Solution™. The platform integrates multiple manufacturing services including: Upstream Processing Cell Culture Development, cGMP Cell Banking, DSP Purification Development, cGMP Clinical & Commercial Manufacturing, Bioconjugation, Aseptic Fill & Finish, Stability Testing, and Analytical Method Development/Assay Verification/Characterization. These core manufacturing services are supported by ancillary services including Manufacturing Strategy Development, Project Management, Regulatory & CMC Support, Quality Control & Quality Assurance, and Biomanufacturing Planning. The company focuses on eliminating manufacturing risk for companies developing complex biologic therapeutics, with applications in bioconjugation (biosimilars) and complex biologics.

Product and service1 record
1Upstream Processing Cell Culture Development
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Lonza
TypeBroad incumbent
Description

World's largest biologics CDMO with comprehensive mammalian, microbial, and cell therapy capabilities. Competes with GBI across all biologics CDMO service lines but at vastly greater scale.

2AGC Biologics
TypeDirect peer
Description

Global biologics CDMO with mammalian and microbial manufacturing, bioconjugation, and fill-finish capabilities. Comparable to GBI across the integrated biologics CDMO service stack, though operating at larger scale.

3Samsung Biologics
TypeBroad incumbent
Description

Mega-scale biologics CDMO with very large single-site commercial manufacturing capacity. Competes with GBI for outsourced biologics manufacturing but with materially greater capacity and pricing leverage.

4KBI Biopharma
TypeDirect peer
Description

Mid-sized biologics CDMO offering cell line development, process development, cGMP manufacturing, and analytical services. Highly comparable to GBI in scale, biologics focus, and integrated service model.

5WuXi Biologics
TypeBroad incumbent
Description

Global biologics CDMO offering end-to-end development and manufacturing including bioconjugation. Comparable service stack to GBI but with much larger global capacity and broader geographic footprint.

6Catalent (Novo Holdings)
TypeBroad incumbent
Description

Large CDMO with biologics manufacturing and fill-finish capabilities. Overlaps with GBI in fill-finish and clinical manufacturing, though Catalent operates across broader modalities and modalities.

7Thermo Fisher Scientific (CDMO services)
TypeBroad incumbent
Description

Operates large-scale biologics and viral vector CDMO services through its Patheon pharma services business. Competes with GBI in clinical and commercial biologics manufacturing at significantly larger scale.

8BioReliance (Merck KGaA / MilliporeSigma)
TypeEmerging player
Description

Provides biopharmaceutical testing, biosafety, and contract manufacturing services. Comparable to GBI in serving biologics developers, though with greater emphasis on testing and characterization services.

9Cytovance Biologics
TypeDirect peer
Description

U.S.-based biologics CDMO providing microbial and mammalian cell culture manufacturing, purification, and aseptic fill-finish. Closely comparable to GBI in services, customer base, and mid-market positioning.

10FUJIFILM Diosynth Biotechnologies
TypeBroad incumbent
Description

Large-scale global biologics CDMO offering cell culture, microbial, and gene therapy manufacturing. Comparable service categories to GBI but at meaningfully greater scale and geographic footprint.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Goodwin Biotechnology

Biopharmaceutical Contract Manufacturinggoodwinbio.com

What Goodwin Biotechnology does

Goodwin Biotechnology, now operating as GBI Biomanufacturing, is a full-service biopharmaceutical contract development and manufacturing organization (CDMO) founded in 1991 and headquartered in Plantation, Florida. The company delivers an integrated platform branded as the Single-Source Solution™, which spans the full biologics manufacturing value chain: upstream cell culture development, cGMP cell banking, downstream purification, cGMP clinical and commercial manufacturing, bioconjugation, aseptic fill and finish, stability testing, and analytical method development and characterization. These core manufacturing services are wrapped with regulatory/CMC support, project management, manufacturing strategy consulting, and quality systems built on a Quality by Design framework.

The company serves biopharmaceutical companies — particularly those developing complex biologic therapeutics, biosimilars, and targeted-delivery biologics requiring bioconjugation — by reducing manufacturing risk and providing integrated development-through-commercial capabilities under one roof. Its go-to-market is direct B2B enterprise sales, supported by participation in industry events (BIO International Convention, BioFlorida) and content marketing. Revenue mechanics are fee-for-service project-based contracts, with pricing determined per engagement; no public rate cards exist. The company is privately held with 51–100 employees, has raised at least $20.7M in disclosed funding (April 2019), and is currently expanding its Broward County facility (May 2026) to add stem cell production capacity targeting Florida's regenerative medicine market.

Goodwin Biotechnology firmographics

Firmographics
Name
Goodwin Biotechnology
Legal name
Goodwin Biotechnology Inc.
Website
https://goodwinbio.com
Company type
Private
Founded year
1991
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Goodwin Biotechnology industry classification

Industry
Product category
Biopharmaceutical Contract Manufacturing
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro primary industry
Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
akta.pro secondary industries
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

  • Biopharmaceutical CDMO services
  • Biologics contract manufacturing
  • CGMP manufacturing services
  • Bioconjugation services
  • Aseptic fill finish

Where Goodwin Biotechnology is headquartered

Location

Headquarters

HQ city
Fort Lauderdale
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Goodwin Biotechnology business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Manufacturing Services: Fee-for-service contract manufacturing model providing preclinical, clinical, and commercial manufacturing services for biopharmaceutical companies. Revenue generated through project-based engagements across development and manufacturing phases.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Goodwin Biotechnology product offering

Product offering

Core offering

Goodwin Biotechnology, operating as GBI Biomanufacturing, is a full-service biopharmaceutical contract development and manufacturing organization (CDMO) that delivers integrated biologics manufacturing services from upstream cell culture development through cGMP clinical and commercial manufacturing, bioconjugation, aseptic fill and finish, stability testing, and analytical characterization. Its Single-Source Solution platform combines development, manufacturing, and project support under one roof for biotech and pharma clients producing complex biologic therapeutics, biosimilars, and regenerative medicine products.

Product overview

GBI (formerly Goodwin Biotechnology) is a full-service biopharmaceutical CDMO (Contract Development and Manufacturing Organization) based in Florida that offers a unified platform called Single-Source Solution™. The platform integrates multiple manufacturing services including: Upstream Processing Cell Culture Development, cGMP Cell Banking, DSP Purification Development, cGMP Clinical & Commercial Manufacturing, Bioconjugation, Aseptic Fill & Finish, Stability Testing, and Analytical Method Development/Assay Verification/Characterization. These core manufacturing services are supported by ancillary services including Manufacturing Strategy Development, Project Management, Regulatory & CMC Support, Quality Control & Quality Assurance, and Biomanufacturing Planning. The company focuses on eliminating manufacturing risk for companies developing complex biologic therapeutics, with applications in bioconjugation (biosimilars) and complex biologics.

Differentiator

Problem solved

Functional benefit

Products and services

  • Upstream Processing Cell Culture Development

Companies that use Goodwin Biotechnology

Customer profile

Segments2 records

Ideal customer profiles1 record

Goodwin Biotechnology technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Goodwin Biotechnology partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Goodwin Biotechnology competitors and assessment

Company assessment

Broad incumbents

  • Lonza: World's largest biologics CDMO with comprehensive mammalian, microbial, and cell therapy capabilities. Competes with GBI across all biologics CDMO service lines but at vastly greater scale.
  • Samsung Biologics: Mega-scale biologics CDMO with very large single-site commercial manufacturing capacity. Competes with GBI for outsourced biologics manufacturing but with materially greater capacity and pricing leverage.
  • WuXi Biologics: Global biologics CDMO offering end-to-end development and manufacturing including bioconjugation. Comparable service stack to GBI but with much larger global capacity and broader geographic footprint.
  • Catalent (Novo Holdings): Large CDMO with biologics manufacturing and fill-finish capabilities. Overlaps with GBI in fill-finish and clinical manufacturing, though Catalent operates across broader modalities and modalities.
  • Thermo Fisher Scientific (CDMO services): Operates large-scale biologics and viral vector CDMO services through its Patheon pharma services business. Competes with GBI in clinical and commercial biologics manufacturing at significantly larger scale.
  • FUJIFILM Diosynth Biotechnologies: Large-scale global biologics CDMO offering cell culture, microbial, and gene therapy manufacturing. Comparable service categories to GBI but at meaningfully greater scale and geographic footprint.

Direct peers

  • AGC Biologics: Global biologics CDMO with mammalian and microbial manufacturing, bioconjugation, and fill-finish capabilities. Comparable to GBI across the integrated biologics CDMO service stack, though operating at larger scale.
  • KBI Biopharma: Mid-sized biologics CDMO offering cell line development, process development, cGMP manufacturing, and analytical services. Highly comparable to GBI in scale, biologics focus, and integrated service model.
  • Cytovance Biologics: U.S.-based biologics CDMO providing microbial and mammalian cell culture manufacturing, purification, and aseptic fill-finish. Closely comparable to GBI in services, customer base, and mid-market positioning.

Emerging players

  • BioReliance (Merck KGaA / MilliporeSigma): Provides biopharmaceutical testing, biosafety, and contract manufacturing services. Comparable to GBI in serving biologics developers, though with greater emphasis on testing and characterization services.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Goodwin Biotechnology social profiles

Digital presence

Goodwin Biotechnology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Goodwin Biotechnology leadership team

Management profile

Number of profiles

Profiles4 records

Goodwin Biotechnology funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Goodwin Biotechnology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Goodwin Biotechnology

What does Goodwin Biotechnology do?

Goodwin Biotechnology, operating as GBI Biomanufacturing, is a full-service biopharmaceutical contract development and manufacturing organization (CDMO) that delivers integrated biologics manufacturing services from upstream cell culture development through cGMP clinical and commercial manufacturing, bioconjugation, aseptic fill and finish, stability testing, and analytical characterization. Its Single-Source Solution platform combines development, manufacturing, and project support under one roof for biotech and pharma clients producing complex biologic therapeutics, biosimilars, and regenerative medicine products.

Is Goodwin Biotechnology a public or private company?

Goodwin Biotechnology is a private company. It is classified as unknown and is currently operating.

When was Goodwin Biotechnology founded?

Goodwin Biotechnology was founded in 1991. It employs 51 to 100 people.

Where is Goodwin Biotechnology based?

Goodwin Biotechnology is headquartered in Fort Lauderdale, United States, in the North America region.

How does Goodwin Biotechnology make money?

One revenue line is on record: contract Manufacturing Services.

Who are Goodwin Biotechnology's main competitors?

Broad incumbents on record are Lonza, Samsung Biologics, WuXi Biologics, Catalent (Novo Holdings), Thermo Fisher Scientific (CDMO services) and FUJIFILM Diosynth Biotechnologies. Direct peers are AGC Biologics, KBI Biopharma and Cytovance Biologics. BioReliance (Merck KGaA / MilliporeSigma) is listed as an emerging player.

Does Goodwin Biotechnology have an API?

No public API is recorded for Goodwin Biotechnology.

What industry is Goodwin Biotechnology in?

Goodwin Biotechnology's product category is Biopharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGAGAA, Cell Therapy CDMO (Autologous/Allogeneic Manufacturing). Its NAICS code is 325414 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GbibioRedefining CDMO Pharma Biopharma ProjectsA promotional company profile describes Goodwin Biotechnology, a US-based CDMO founded in 1992 offering process development, cGMP manufacturing, cell line development, bioconjugation and aseptic fill/finish for biologics. It cites 30 years of CDMO experience, 20 years in antibody drug conjugates with over 50 IND filings, 150+ clients and 500+ projects, and a 38,000 sq. ft. facility. A commercial expansion tied to a growth capital fund raise is slated for completion in 2023.PR NewswireGoodwin Biotechnology Announces the Appointment of Darrin T. Schellin as Chief Executive OfficerGoodwin Biotechnology announced the appointment of Darrin Schellin as Chief Executive Officer and member of the board of directors, effective immediately, based in Florida. Schellin brings decades of life sciences experience, including leading Alliance Medical Products through rapid growth until its sale to Siegfried Holding AG, followed by six years running Siegfried's global drug products business across five US and European sites. The company stated the appointment is designed to accelerate growth and scale operations as it positions itself to expand its CDMO services for biopharmaceutical clients.PR NewswireGoodwin Biotechnology Announces the Appointment of Kent Payne, Ph.D. and Brandon Price, Ph.D. to its Board of DirectorsGoodwin Biotechnology, a Florida-based contract development and manufacturing organization, announced the appointments of Brandon Price, Ph.D. and Kent Payne, Ph.D. to its Board of Directors on August 19, 2019. Dr. Price brings over 40 years of biopharmaceutical industry experience including prior service as Goodwin's CEO, while Dr. Payne contributes more than 30 years of operational and strategic expertise in the biotechnology and pharmaceutical sectors. The company stated these additions provide industry leadership to guide its expansion as it continues offering single-source contract manufacturing services for complex biopharmaceuticals.PR NewswireGoodwin Biotechnology Secures Significant Institutional Investment in New Round of Growth Capital FinancingGoodwin Biotechnology, a full GMP FDA-registered biopharmaceutical contract development and manufacturing organization, announced completing its largest ever growth capital financing round with Signet Healthcare Partners, a New York-based healthcare growth equity firm. The investment will fund doubling cGMP manufacturing capacity as Goodwin expands from clinical support into commercial manufacturing, with two Signet investors joining its board of directors. The capital will support development of capabilities for cutting-edge biologics products requiring small-to-mid volumes as the company responds to growing market demand.PR NewswireGoodwin Biotechnology Invests in Doubling its Space Available for cGMP Capacity as it Readies for Further Expansion of its Biopharmaceutical Manufacturing BusinessGoodwin Biotechnology, a US-based FDA-registered Contract Development and Manufacturing Organization, has purchased the two-acre site where it operates in Fort Lauderdale, Florida, and is investing in doubling its cGMP manufacturing capacity to support commercial production needs for biopharmaceutical clients. The expansion includes more than doubling development bioreactor laboratory scale and expanding purification, bioconjugation, and method development capabilities. The company positions this as part of a strategic growth roadmap to fill a niche for small to mid-volume biopharmaceutical manufacturing, which it views as the future of the industry.PR NewswireRadimmune Therapeutics Selected Goodwin Biotechnology for Process Development through cGMP Manufacturing of their IgG Monoclonal Antibody and ConjugateRadimmune Therapeutics has selected Goodwin Biotechnology to develop and manufacture its lead therapeutic oncology candidate, an IgG monoclonal antibody conjugate radiolabeled with 213Bi, for a Phase I clinical study targeting melanoma. The partnership leverages Goodwin's process development and cGMP manufacturing capabilities, with radiolabeling development led by Dr. Ekaterina Dadachova at the University of Saskatchewan. Radimmune aims to launch its Phase 1 clinical trial in 2019, advancing this novel Radioimmunotherapy approach that uses alpha-emitting radionuclides targeted to cancer cells.PR NewswireTelix Pharmaceuticals Selects Goodwin Biotechnology as Manufacturing Scale-up PartnerTelix Pharmaceuticals has selected Goodwin Biotechnology as its manufacturing scale-up partner for the cGMP production of its renal cancer imaging antibody drug conjugate, TLX-250. This partnership aims to optimize the manufacturing process to support Telix's Phase III clinical studies and future commercialization. The collaboration leverages Goodwin's expertise in radiopharmaceuticals and antibody conjugation.PR NewswireGoodwin Biotechnology and For-Robin Collaborated to Generate a Unique Antibody : Drug Conjugate (ADC) that Shows Promise in Enhancing the Treatment of a Variety of CancersGoodwin Biotechnology and For-Robin announced a collaboration resulting in an antibody-drug conjugate (ADC) called JAA-F11 : DM1, with research published in the peer-reviewed journal Neoplasia showing promising cytotoxic activity against multiple cancer cell lines including breast and lung cancers. The ADC demonstrated potent tumor growth suppression in mouse xenograft models of triple-negative breast cancer, representing a significant advance given the absence of targeted therapies for this cancer subtype. The companies selected site-directed conjugation as a superior manufacturing approach over random conjugation, enabling the ADC to achieve higher antigen binding compared to the commercially available ADC Kadcyla.PR NewswireFinding Solutions that Help a Unique Monoclonal Antibody Advance the Fight Against Metastatic Breast CancerA peer-reviewed study published in Cancer Biotherapy and Radiopharmaceuticals describes the collaborative work between Goodwin Biotechnology and Panacea Pharmaceuticals on a radiolabeled antibody conjugate (PAN-622) targeting HAAH for metastatic breast cancer imaging and potential treatment. The research overcame initial conjugation challenges by using a proprietary site-directed approach, achieving 93% radiolabeling efficiency, and demonstrated significant reduction in primary tumor weight (p=0.04) in murine models with the 213Bi-DTPA-PAN-622 conjugate. The companies indicated plans to explore the conjugate in other cancer types and to investigate adding cytotoxic payloads for therapeutic applications.PR NewswireThe Minneapolis Medical Research Foundation Selects Goodwin Biotechnology to Help Develop and Manufacture Two Vaccines to Treat Opioid AddictionGoodwin Biotechnology was selected by the Minneapolis Medical Research Foundation to develop and manufacture two vaccines aimed at treating opioid addiction. The research is funded by a three-year grant from the National Institute on Drug Abuse to prepare these vaccines for clinical evaluation.